FORM 4				OMB APPROVAL				
Check this box if no longer subject to Sect Form 4 or Form 5 obligations may continu Instruction 1(b). Check this box to indicate that a transaction made pursuant to a contract, instruction or plan for the purchase or sale of equity secut the issuer that is intended to satisfy the affidefense conditions of Rule 10b5-1(c). See Instruction 10. (Print or Type Responses)	e. <i>See</i> n was written rities of Filed pursuan	UNITED STATES SECURITIES AND EXCHANGE CO Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP t to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h)	P OF SECURITIES	OMB Number: Estimated average burden heresponse	3235-028 ours per 0			
Name and Address of Reporting Person * Satchi-Fainaro Ronit		2. Issuer Name and Ticker or Trading Symbol Teva Pharmaceutical Industries Limited [TEVA]		5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner				
(Last) (First) C/O Teva Pharmaceutical Industries Ltd. 124 Dvora HaNevi'a St.,	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 06/05/2025	Officer (give title belo		below)			
(Street)		4. If Amendment, Date Original Filed (Month/Day/Year)		6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person				
Tel Aviv, L3 6944020								
(City) (State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1.Title of Security (Instr. 3)	Date (Month	Execution Date, if any	3. Transaction Code (Instr. 8)		4. Securi Disposed (Instr. 3,	of (D)	,	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. 7. Nature Ownership Form: Beneficia Direct (D) or Indirect (I) (Instr. 4)		
		(Month/Day /Year)	Code	V	Amount	(A) or (D)	Price		or Indirect		
Ordinary Shares (1)	06/06/2025		M		9,632	A	(2)	97,909	D		

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month /Day/Year)	3A. Deemed Execution Date, if any (Month/Day /Year)	4. Transact Code (Instr. 8)		Derivative Securities		Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		(Instr. 5)	of Derivative Securities Beneficially	Ownership Form of Derivative Security:	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Following	Direct (D) or Indirect (I) (Instr. 4)	
Restricted Share Units	(2)	06/06/2025		М			9,632	(3)	(3)	Ordinary Shares ⁽¹⁾	9,632	\$ 0	0	D	
Restricted Share Units	(2)	06/05/2025		A		14,492		(4)	(4)	Ordinary Shares ⁽¹⁾	14,492	\$ 0	14,492	D	

Explanation of Responses:

- 1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- 2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
- 3. Restricted share units were granted on June 6, 2024 and vested on June 6, 2025.
- 4. Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.



Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.